MODALITY: BiTE® TECHNOLOGY
CLINICAL TRIALS:
Study title Phase Status
Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)Phase 3Recruiting
Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaPhase 1/2Active, not recruiting
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALLPhase 3Recruiting
An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the USRetrospectiveRecruiting
Observational Study of BlinatumomabObservationalRecruiting
A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaPhase 1Recruiting
Study of AMG 596 in Patients With EGFRvIII Positive GlioblastomaPhase 1Recruiting
Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple MyelomaPhase 1Recruiting
Effect of Blinatumomab on MRD in DLBCL Subjects Post aHSCTPhase 2Recruiting
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's LymphomaPhase 1Recruiting
Safety and Efficacy of Blinatumomab in Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell LymphomaPhase 2Active, not recruiting
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHLPhase 2/3Recruiting
Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)Phase 1Recruiting